

30th October 2026

IOLCP/CGC/2026

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051

Security Symbol: IOLCP

BSE Limited,

Pheroze Jeejeebhoy Tower,
Dalal Street, Mumbai- 400 001

Security Code: 524164

Subject: Press Release – Financial Results for the quarter and half year ended 30th September 2026

Dear Sir,

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release dated 30th October 2026 with respect to the financial results of the Company for the quarter and half year ended 30th September 2026.

You are requested to take the same on record.

Thanking You,

Yours faithfully,

for IOL Chemicals and Pharmaceuticals Limited

ABHAY
RAJ
SINGH

Digitally signed
by ABHAY RAJ
SINGH
Date: 2026.10.30
20:02:43 +05'30'

Abhay Raj Singh

Sr. Vice President & Company Secretary



IOL Chemicals And Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited Reports Q2 & H1 FY27 Results *Records Highest-Ever Quarterly Revenue, EBITDA & PAT*

Ludhiana, 30th October 2026: IOL Chemicals and Pharmaceuticals Ltd., one of the leading Active Pharmaceutical Ingredient (API) manufacturers, announced its Unaudited Financial Results for the quarter and half year ended 30th September 2026.

Q2 FY27 Financial Performance Snapshot (Y-o-Y)

(Standalone)


Revenue from Operations	EBITDA	PAT
₹795.0 Cr	₹114.9 Cr	₹65.0 Cr
 40.1%	 79.6%	 116.8%

Key Standalone Financial Highlights

Particulars (₹ Cr)	Q2 FY27	Q2 FY26	Y-o-Y	H1 FY27	H1 FY26	Y-o-Y
Revenue from Operations	795.0	567.5	40.1%	1551.3	1119.2	38.6%
EBITDA	114.9	64.0	79.6%	226.6	133.5	69.7%
EBITDA Margin (%)	14.4%	11.1%	+321 bps	14.5%	11.8%	+270 bps
PAT	65.0	30.0	116.8%	129.5	64.0	102.5%
PAT Margin (%)	8.1%	5.2%	+290 bps	8.3%	5.6%	+263 bps

Segment Highlights

(In ₹ Cr)



Commenting on the performance, Mr. Vikas Gupta, Joint Managing Director said,

“We are encouraged by our performance in Q2 FY27, supported by healthy demand across key products and improved operational efficiencies. Our diversified business model has enabled us to sustain growth momentum amid continued geopolitical uncertainties and evolving global market conditions. Better product mix and operating efficiencies also contributed to a 321-basis-point year-on-year expansion in EBITDA margin.

Our Pharmaceuticals business continued to perform well, backed by healthy demand across the portfolio. A key highlight was the growing contribution of our non-Ibuprofen portfolio, which registered approximately 70% year-on-year revenue growth and accounted for 45% of pharmaceutical revenue during the quarter, compared with 38% in Q2 FY26. This underscores the progress of our diversification strategy and our efforts to build a broader pharmaceutical portfolio.

The Chemicals business also recorded a significant improvement, supported by healthy demand across products. The segment's EBIT contribution increased to approximately 7% from 1% in the corresponding quarter last year, reflecting improved realisations and operating performance.

Looking ahead, we are focused on leveraging our established manufacturing capabilities to move further up the value chain. Our forward integration into CDMO and formulation manufacturing is a natural extension of our process expertise, enabling us to provide a wider range of solutions to existing customers, deepen business relationships and unlock new growth opportunities.

Going forward, our priorities will remain centred on portfolio diversification, operational excellence and expanding our presence in higher-value manufacturing, while continuing to strengthen our leadership in established product categories. We believe these initiatives will reinforce our competitive positioning and support sustainable long-term growth.”



About IOL Chemicals and Pharmaceuticals Ltd.

IOL Chemicals and Pharmaceuticals Ltd. (IOLCP), established in 1986 and headquartered in Ludhiana, Punjab, is a leading Indian manufacturer of Active Pharmaceutical Ingredients (APIs) and specialty chemicals. It is the world's largest producer of Ibuprofen with a 30% global market share, among the largest global producers of Iso Butyl Benzene (IBB), and a key manufacturer of Ethyl Acetate in India. IOLCP's API portfolio spans key therapeutic areas such as pain management, anti-convulsants, anti-diabetics, and cardiovascular care. With exports to over 80 countries—including the USA, UK, China, and Germany—and strong regulatory approvals, the company is well-positioned for global growth. Its backward-integrated operations and ongoing capacity expansion support long-term scalability and resilience.

Contact Details

IOL Chemicals & Pharmaceuticals Ltd.	Investor Relations: MUFG Intime India Pvt. Ltd.
	
CIN: L24116PB1986PLC007030	Ms. Prachi Ambre prachi.ambre@in.mpms.mufg.com
Mr. Abhay Raj Singh Sr. VP & Company Secretary investor@iolcp.com	Mr. Irfan Raeen irfan.raeen@in.mpms.mufg.com
	Meeting Request Link Website: https://in.mpms.mufg.com/

Safe Harbor Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.